Advancing Research on Milk Thistle
This special issue on milk thistle (Figure 1 ), guest edited by Kara Kelly, Janice Post-White, and Elena Ladas, recognizes recent advances in research on milk thistle. This herb, used since the times of the ancient Greeks and Romans, has recently become of special interest in oncology with the research currently being conducted at Columbia University on its use in pediatric oncology to protect the liver during chemotherapy with potentially hepatotoxic drugs. It is also frequently used by adult cancer patients for similar purposes, usually on a self-medication basis. In support of the Columbia studies, Kelly, Post-White, and Ladas have recruited experts on milk thistle to review all aspects of research on this herb. We have encouraged the editors and authors to recognize the interests of clinicians in the articles in this issue, and we find that there is indeed much material of solid clinical relevance and direct applicability.
Post-White, Elena Ladas, and Kelly, in their introductory article, summarize the current status of research on milk thistle, focusing on the articles in this issue. Their main research involvement has been in the application of milk thistle in oncology, specifically as an agent to protect the liver during administration of cytotoxic chemotherapy in pediatric settings. The main thrust of the articles in this issue is the application of milk thistle to oncology, both in the preventive setting and as an adjunct to treatment. Interestingly, the exploration of milk thistle's application in cancer followed publication of 2 case studies that created interest in its potential use in oncology. This is certainly an example of the usefulness of case studies, which constitute a very low level of evidence but are nevertheless of continuing importance.
The article by Heather Greenlee, Kathy Abascal, Eric Yarnell, and Elena Ladas focuses on the varieties of clinical uses of milk thistle in oncology. This article is most intriguing for the clinician. Milk thistle has a centuries-old history in folk medicine, with applications as a digestive aid, anti-inflammatory, galactogogue, and several other uses. It plays a role in cleansing and detoxification, concepts that continue to be important in alternative medical systems. The authors clarify the meaning and context of these ideas and their importance. It is useful for conventional practitioners who work with complementary and alternative medicine (CAM) healers and patients using CAM to understand the significance of these ideas, and this article is worth reading for that section alone. The authors point out that several modern uses of milk thistle-counteracting damage due to exposure to alcohol, drugs, solvents, or Amanita phalloides toxin-are considered analogous to chemotherapeutic drug exposures. This has been the foundation for the interest among patients and practitioners in applying milk thistle during chemotherapy. Because hepatotoxicity is a frequent cause of dose reductions in adult and pediatric chemotherapy regimens, finding agents that could reduce this toxicity is of major interest. The use of milk thistle in cardiovascular disease and diabetes, common comorbidities in cancer patients, is also discussed. An interesting point in the article is the discussion, in reference to liver diseases, of the fact that most CAM clinicians do not use milk thistle as a sole therapy in established or serious liver diseases. It is commonly used with other hepatoprotective agents and antioxidants. Only a few human studies have attempted observations of patients on complex protocols that include milk thistle. The article by David Kroll, Heather Shaw, and Nicholas Oberlies deals with the nomenclature of milk thistle phytochemicals. This may seem like the farthest thing from the interests of clinicians. But these authors make some critical points. First, they point out that milk thistle extracts in commerce are correctly called silymarin-but that silymarin is not a single phytochemical. Rather, it is a mixture of different phytochemicals, which have different effects in and on the body. The constituents silybin B and taxifolin, for instance, have estrogenic effects, whereas isosilybin B is the most potent antiproliferative compound in studies of prostate cancer cells. As the development of botanical drugs proceeds, we are very likely to see silymarin products that contain different proportions of these phytochemicals for different uses. Kroll and his colleagues additionally point out that pharmacokinetic studies and observations have so far concluded that milk thistle does not have significant drug interactions at the levels commonly used. However, some research studies are beginning to use very high doses of silymarin. These doses may very well have different pharmacokinetic effects than low doses, and the assumption that milk thistle lacks significant drug interactions may prove to be erroneous for high doses.
The article of Gagan Deep and Rajesh Agarwal delves deeply into the molecular mechanisms of silymarin phytochemicals in carcinogenesis. What is very intriguing to the clinician in this excellent and scholarly article is the variety of clinically interesting molecular targets that are affected. Many of these same molecules are relevant in drug development, and some are in fact targets of conventional molecular target drugs. Among the more interesting effects of silymarin they list are inhibiting the activation of receptor tyrosine kinase EGFR, causing cell cycle arrest in cancer cells, promoting apoptosis, completely inhibiting mRNA expression of TNFα as well as of IL-1α protein, modulating COX2, and decreasing nuclear levels of androgen receptor, important in prostate cancer. Silymarin also decreases NF-κB transcriptional activity in prostate cancer cells. This plant extract is a multitargeted molecular agent in itself, and Deep and Agarwal rightly suggest it may have application in inhibiting both carcinogenesis and malignancy. It is obvious that this herb is, like several others, a potential treasure trove for the oncologist. Another reassuring aspect of the several anticancer activities of silymarin is that giving it alongside chemotherapeutic drugs could possibly give rise to positive synergistic effects, rather than raising concerns about somehow antagonizing the antitumor activities of the conventional drugs.
The article by Maria Comelli, Ulrich Mengs, Marco Prosdocimi, and Carl Schneider examines the pharmacology of silymarin at the cellular level as well as its pharmacological and pharmacokinetic aspects. Several interesting gems are found in this article. They reference a pharmacokinetic study on silymarin given with irinotecan, which found that silymarin did not change the kinetics or distribution of this drug, a reassuring finding for those interested in using it adjunctively with chemotherapy. They also make the point that the damage to liver cells caused by chemotherapy drugs is basically similar to that caused by acetaminophen, antipsychotics, and other agents for which silymarin has been found to be hepatoprotective. These authors explore the antioxidant activity of silymarin in detail, as well as the time course of its hepatoprotective action. The conclusion of the article stresses the potential benefits of silymarin use before and during toxic insults to the liver, based on both its pharmacological activities and its pharmacokinetic properties. This gives silymarin a particularly useful profile in dealing with hepatotoxic chemotherapy drugs.
I could not help being intrigued, when reading the article of Carmen Tamayo and Suzanne Diamond, by the case report of the family in California who were poisoned by Amanita mushrooms that they collected locally and ate at home. These unfortunate patients were nearing death from liver failure, a well-known effect of Amanita's hepatotoxic compounds. However, all but 1 of them survived, due to the provision of an intravenous silibinin product by Madaus Pharma, with special approval by the FDA. Although this is not a cancer report, it illustrates the apparent safety and efficacy. I cannot help but hope that further work on like this apparently invaluable product is eventually undertaken, as our investigation of the properties of natural products proceeds under FDA regulations. It would certainly be a boon to the victims of poisoning by Amanita, which is apparently spreading explosively through the forests of California (http://www.npr.org/ templates/story/story.php?storyId=7251327). The efficacy of silymarin in mushroom poisoning highlights another suggestion in the Tamayo and Diamond article. In reviewing current literature, the indications are that milk thistle products do not work so well on longestablished diseases such as chronic hepatitis, except perhaps in amelioration of some symptoms. Rather, the most intriguing results have been in situations where silymarin is given simultaneously with, or soon after, the insult to the liver. This is certainly the model that the Columbia group is using in testing silymarin in oncology and is very consistent with the model proposed by the Comelli et al article.
Stephen Sagar provides an overview that both affirms the interesting potentials of silymarin in chemotherapy and strikes a cautionary note about its wider applications in cancer. Because of silymarin's strong antioxidant activity and broad spectrum of cellular protection, he raises concerns that it may protect tumors from radiation. A radiation-protective effect has been found for silymarin in the kidney in an animal model, and it is unknown whether silymarin would differentially protect normal and cancer cells. Silymarin also has estrogenic effects (perhaps related to its use as a galactogogue), which could potentially stimulate the growth of estrogensensitive tumors, especially if given over a long period. Little is known about these effects. Sagar also discusses the regulatory steps that silymarin investigators need to go through to thoroughly demonstrate its usefulness in oncology. Echoing the concerns raised in the article of Kroll et al, this reminds us that it will be necessary to strictly define the phytochemistry of the products used in clinical trials and to remember the different properties of silymarin's distinct chemical components.
Our entire editorial staff thanks the guest editors of this special focus issue for their hard work in recruiting these articles, interacting with their authors, and organizing this overall effort. Without their stellar work, this issue would have been impossible. Because of their efforts, the scientific community will have a resource to guide and inspire further research on this very interesting herbal medicine.
Filling out this issue are 2 more articles. Mary Koithan, Iris Bell, Opher Caspi, Lynn Ferro, and Victoria Brown carry forward the approach to studying integrative medicine as a whole system that was discussed in our December 2006 special issue, to which Dr Koithan contributed an article. One of our tasks in integrative medicine today is to figure out how and if different models of integrative medicine function, especially from the point of view of patients. Koithan et al thus have carried out a qualitative study on patients attending the integrative clinic at the University of Arizona, comparing the impressions of cancer patients with other clinic patients. One of the features of qualitative work that I particularly appreciate is the voices of the research participants coming directly to the reader. Some intriguing and cheering quotes from patients in the groups interviewed by Koithan and her colleagues are found in this article. Two of the patients reported being referred to the integrative clinic by their doctors or oncologists, a sign of the increasing acceptance of integrative approaches throughout the conventional medical world. The listening and caring that these patients experienced with their integrative doctors were exemplary. My only problem in reading this finding is their perception that their integrative doctors were so much better in this way than some of their conventional physicians. Surely listening and communicating a caring approach to patients should be skills that every health care professional is steeped in from the start of their training-not just a property of integrative doctors. The dismissive attitude of some conventional doctors toward their patients' questions and their wishes for holistic programs, though, continues to be disappointing.
Finally, we include a study of the phytochemical amentoflavone and its effect in inhibiting lung metastases in an animal model. The metastatic process deserves the thorough study that the initial processes of carcinogenesis have received over the years. The authors of this article, C. Guruvayoorappan and Girija Kuttan, report that amentoflavone inhibits such factors as the expression of tissue inhibitor of metalloproteinase genes, as well as the production of inflammatory cytokines that are relevant in metastasis. This makes amentoflavone a very interesting compound for further research.
